Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer

Uysal M., OZDOGAN M., KARGI A., GUNDUZ S., GOKSU S. S., TATLI A. M., ...Daha Fazla

JOURNAL OF BUON, cilt.19, sa.4, ss.980-984, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2014
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.980-984
  • Anahtar Kelimeler: cyclophosphamide, etoposide, maintenance therapy, metronomic oral therapy, ovarian cancer, RANDOMIZED PHASE-III, PLATINUM-RESISTANT, INTERGROUP TRIAL, THERAPY, CARCINOMA, PACLITAXEL, CHEMOTHERAPY, CARBOPLATIN, TOPOTECAN, WOMEN
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Purpose: In ovarian cancer permanent remission may be provided with optimal cytoreductive surgery and adjuvant chemotherapy. However survival is short in patients with residual macroscopic disease after surgery or recurrent ovarian cancer. Applicable maintenance therapies with low toxicity are required to prolong progression-free survival (PFS) for patients with no curative treatment options. In this study, we investigated the effect of maintenance metronomic oral cyclophosphamide and etoposide (CE) in ovarian cancer patients with post operative residual or recurrent disease.